Notably, while RPL26L1 has not been previously associated with OSA, our multi-platform analysis demonstrates its significant upregulation in OSA patients (RT-PCR), strong phenotypic correlation with OSA and MDD (WGCNA analysis), diagnostic utility for both conditions (ROC curve), and linkage to immune cell infiltration (ssGSEA analysis), collectively establishing its therapeutic relevance for OSA-MDD comorbidity. Here, RPL26L1 is linked to obstructive sleep apnea syndrome.